secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-110883
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx Q3 net loss $50.5M; enters ophthalmology collaboration with Lilly for $75M upfront
--------------------------------------------------------------------------------

- Collaboration with Lilly: upfront $75M, eligible for >$400M milestones and tiered royalties on ocular programs.
- Cash $14.8M at Sept 30; with Lilly $75M and Hologen $150M expected, runway into H2 2027 covers $75M debt due Aug 2026.
- Net loss $50.5M ($0.62/share) vs $39.3M ($0.55) YoY; service revenue fell to $0.4M from $10.9M as J&J PPQ substantially completed.
- AAV-hAQP1 Phase 2 enrollment target end of 2025; positive data could support BLA filing early 2027.
- AAV-GAD Phase 3 for Parkinson's expected to initiate in coming months; RMAT designation granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465925110883/0001104659-25-110883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465925110883/mgtx-20251113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer